Evotec SE (EVO) Income from Continuing Operations (2009 - 2025)
Evotec SE (EVO) reported Income from Continuing Operations of 120365220.22 for Q4 2025, up 42.5% on a YoY basis from 84469503.11 in Q4 2024, and down 240274.03% sequentially from 50074.14 in Q3 2025.
Evotec SE (EVO) Income from Continuing Operations (2009 - 2025) Analysis & Trends
Evotec SE (EVO) has 9 years of Income from Continuing Operations data on file, last reported at 120365220.22 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 42.5% year-over-year to 120365220.22; the trailing twelve-month figure through Dec 2025 stood at 329789072.46 (down 10.08% YoY), and the FY2025 full-year result was 120498292.51, up 42.49% from the prior year.
- Income from Continuing Operations declined to 120365220.22 in Q4 2025, from 50074.14 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 246254899.13 in Q4 2021 to a low of 209314347.96 in Q4 2024.
- A 5-year average of 23523562.29 and a median of 22125.42 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 8771.52% in 2021 and plunged 361.5% in 2024, its largest moves.
- Tracing EVO's Income from Continuing Operations over 5 years: stood at 246254899.13 in 2021, then sank by 172.83% to 179338481.97 in 2022, then surged by 49.68% to 90236548.48 in 2023, then sank by 131.96% to 209314347.96 in 2024, then surged by 42.5% to 120365220.22 in 2025.
- Business Quant data shows EVO's Income from Continuing Operations at 120365220.22 in Q4 2025, 50074.14 in Q3 2025, and 209314347.96 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Evotec SE | 346.06 Mn | 345.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.37 Mn |
| Sep 30, 2025 | -50,074.14 |
| Dec 31, 2024 | -209.31 Mn |
| Sep 30, 2024 | -59,430.15 |
| Dec 31, 2023 | -90.24 Mn |
| Sep 30, 2023 | 22,726.50 |
| Jun 30, 2023 | -13,888.14 |
| Dec 31, 2022 | -179.34 Mn |
| Sep 30, 2022 | 39,779.45 |
| Jun 30, 2022 | -22,125.42 |
| Mar 31, 2022 | -72,868.90 |
| Dec 31, 2021 | 246.25 Mn |
| Sep 30, 2021 | 160,102.41 |
| Jun 30, 2021 | 73,489.46 |
| Mar 31, 2021 | 68,554.02 |
| Dec 31, 2020 | 7.47 Mn |
| Sep 30, 2020 | 1,804.68 |
| Dec 31, 2019 | 41.30 Mn |
| Sep 30, 2010 | 1,282.23 |
| Jun 30, 2010 | 2,369.92 |